About this episode

The episode discusses Biogen's new data on tau-focused approaches to neurodegenerative diseases, recent developments in psychedelics, and the impact of AstraZeneca and Ionis' late-stage failure in the ATTR-CM space.

Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

Topics covered

• neurodegenerative disease
• psychedelics
• ATTR-CM
• tau-focused approach
• clinical data
• FDA guidance

Keywords

• Biogen
• tau
• psychedelics
• Compass Pathways
• FDA
• ATTR-CM
• AstraZeneca
• Ionis
• antisense therapeutic
• Alzheimer's

Mentioned in this episode

Organizations: Biogen, Compass Pathways, FDA, AstraZeneca, Ionis

Products: antisense therapeutic

More episodes of BioSpace

• The future of pain relief: Exploring opioid alternatives · July 16, 2026 · 19 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• From sequence to scale: Gene editing’s new era in biologics manufacturing · July 10, 2026 · 21 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water · July 1, 2026 · 23 min
• The Golden Triangle and the gaps: Rethinking UK biotech · June 25, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.